Group 1 - Recently, Wuxi Guolian Tongzhi Technology Industry Investment Partnership (Limited Partnership) was established with a capital contribution of 1.22 billion RMB [1] - The executive partner of the partnership is Guolian Tongbao Capital Investment Co., Ltd., which is a subsidiary of Guolian Minsheng [1] - The business scope includes venture capital, investment activities with self-owned funds, and private equity investment management [1] Group 2 - The partnership is registered as a limited partnership and is classified under capital market services [2] - The establishment date of the partnership is September 10, 2025, and it has no fixed term of operation [2] - The main operating location is in Wuxi City, Jiangsu Province, specifically at Guangrui Road [2]

Core Viewpoint - 2025 is a pivotal year for the reform and high-quality development of China's capital market, with Guolian Minsheng Securities focusing on integrating investment banking services and establishing a new strategic direction centered on "industrial investment banking, technology investment banking, and wealth investment banking" [1] Group 1: Cultural Integration - The integrated Guolian Minsheng Securities retains the cultural essence of Huaying Securities while incorporating the diligent spirit of Minsheng Securities, forming a unique cultural advantage that combines "boutique investment banking" with "service-oriented" practices [2] - In the first half of 2025, the company ranked seventh in both the number of IPOs and the total underwriting amount, with the number of IPO applications placing it among the top five in the industry, demonstrating the effectiveness of cultural integration [2] Group 2: Compliance Foundation - The company emphasizes that "compliance and risk control are the lifelines of investment banking," integrating the compliance management experiences of both Huaying and Minsheng Securities to create a unique compliance risk control model [3] - The three-line defense system has become a core part of the company's compliance culture, enhancing risk control while promoting business development [3] Group 3: Professional Empowerment - The company has evolved its business model from "investment + investment banking" to "investment-insurance linkage + industry groups," marking a significant breakthrough in professional development [4] - The establishment of industry groups covering 12 cutting-edge fields aims to enhance the company's ability to provide comprehensive financial services and foster a sustainable professional growth capability [4] Group 4: Service to the Real Economy - The company is committed to serving the real economy, focusing on "deep regional engagement and precise industry cultivation" as a core path for cultural and business integration [6] - It has established a presence in key cities and is actively researching local industry trends to provide comprehensive financial services tailored to strategic emerging industries [6] Group 5: Cultural Implementation - The company promotes deep cultural integration through a system supported by party leadership, institutional backing, and cultural empowerment, enhancing employee engagement and cultural recognition [7] - It has received multiple market awards, further enhancing its influence in the fields of industrial, technology, and wealth investment banking [7] Group 6: Future Outlook - Looking ahead to the "14th Five-Year Plan," the company aims to solidify its three pillars of "industrial investment banking, technology investment banking, and wealth investment banking," continuously transforming cultural advantages into business competitiveness [8]

天眼查工商信息显示，近日，无锡国联通智科技产业投资合伙企业（有限合伙）成立，执行事务合伙人 为国联通宝资本投资有限责任公司，出资额12.2亿人民币，经营范围包括创业投资、以自有资金从事投 资活动等。股权全景穿透图显示，该合伙企业由国联民生旗下国联通宝资本投资有限责任公司、国联人 寿保险股份有限公司共同出资。 ...

Core Viewpoint - Company maintains a "Buy" rating for Innovent Biologics (01801), highlighting its unique global R&D and commercialization capabilities as a leading innovative drug company in China [1] Financial Performance - In H1 2025, total revenue reached 5.953 billion yuan, a year-on-year increase of 50.6%, with profit turning positive at 834 million yuan [1] - Product revenue was 5.234 billion yuan, up 37.3% year-on-year, while licensing fee income surged to 666 million yuan, a 474% increase [2] - Gross margin improved to 86.0%, up 3.1 percentage points, and R&D expenses were optimized to 1.009 billion yuan, down 28% [2] - As of June 30, 2025, cash reserves were approximately 11 billion yuan, providing solid support for global innovation [2] Pipeline Development - The core pipeline IBI363 has initiated a global Phase III clinical trial for squamous NSCLC, with promising data presented at the ASCO annual meeting [3] - Significant progress in multiple pipelines includes the initiation of Phase III studies for IBI343 in pancreatic cancer and IBI354 in ovarian cancer [4] - The company is advancing its collaboration with Roche on IBI3009, conducting MRCT clinical studies in Australia, China, and the U.S. [4]

Core Viewpoint - Company maintains a "buy" rating for Innovent Biologics (01801), highlighting its unique global R&D and commercialization capabilities as a leading innovative drug company in China [1] Financial Performance - In H1 2025, total revenue reached 59.53 billion yuan, a year-on-year increase of 50.6%, with profit turning positive at 8.34 billion yuan [1] - Product revenue was 52.34 billion yuan, up 37.3% year-on-year, while licensing fee income surged to 6.66 billion yuan, a 474% increase [2] - Gross margin improved to 86.0%, up 3.1 percentage points, and R&D expenses were optimized to 10.09 billion yuan, down 28% [2] - As of June 30, 2025, cash reserves were approximately 11 billion yuan, providing solid support for global innovation [2] Pipeline Development - The core pipeline IBI363 has initiated a global Phase III clinical trial, showing promising efficacy in cold tumors and IO-resistant populations [3] - Significant progress in multiple pipelines includes the initiation of Phase III studies for CLDN18.2 ADC (IBI343) in pancreatic cancer and HER2 ADC (IBI354) in ovarian cancer [4] - The company has established a global collaboration with Roche for IBI3009 (DLL3 ADC), advancing multi-regional clinical trials in Australia, China, and the U.S. [4]

Company Overview - Guolian Minsheng Securities Co., Ltd. is located in Wuxi, Jiangsu Province, and was established on January 8, 1999, with its listing date on July 31, 2020 [1] - The company’s main business includes brokerage and wealth management, investment banking, asset management and investment, credit trading, and securities investment [1] - The revenue composition is as follows: securities investment business 42.05%, brokerage and wealth management 29.79%, investment banking 13.56%, credit trading 7.48%, asset management and investment 7.34%, and others 0.83% [1] Financial Performance - As of June 30, 2025, Guolian Minsheng reported a net profit of 1.127 billion yuan, a year-on-year increase of 1185.19% [2] - The company has distributed a total of 1.289 billion yuan in dividends since its A-share listing, with 720 million yuan distributed over the past three years [3] Stock Performance - On September 11, the stock price increased by 2.01%, reaching 11.19 yuan per share, with a trading volume of 500 million yuan and a turnover rate of 1.74% [1] - The total market capitalization is 63.566 billion yuan [1] - Year-to-date, the stock price has decreased by 16.89%, with a 2.36% decline over the last five trading days and a 3.20% decline over the last 20 days, while it has increased by 14.14% over the last 60 days [1] Shareholder Information - As of June 30, 2025, the number of shareholders is 94,600, a decrease of 6.40% from the previous period, with an average of 25,271 circulating shares per person, an increase of 6.84% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 43.7824 million shares, an increase of 14.7418 million shares from the previous period [3]

Group 1 - The cement industry is experiencing a gradual improvement in its prosperity, with corporate profit elasticity being released while still remaining near historical bottom levels [1] - The average price of cement per ton in H1 2025 was 394 yuan, showing a year-on-year increase of 21 yuan or 6%, while the average price difference between cement and coal was 336 yuan, up by 38 yuan or 13% year-on-year [1] - In H1 2025, the revenue of 18 listed companies in the cement industry was 141.7 billion yuan, a year-on-year decrease of 7%, while net profit attributable to shareholders was 5.5 billion yuan, a year-on-year increase of 789% [2] Group 2 - Most cement companies saw a significant improvement in net profit per ton in H1 2025, with the gross profit per ton for Huaxin Cement increasing by 37 yuan year-on-year, mainly due to the expansion of overseas production capacity [3] - The overall capital expenditure of sample cement companies in H1 2025 was 9.9 billion yuan, a decrease of 3.3 billion yuan year-on-year, indicating a significant reduction in capital spending [4] - Only Conch Cement and China Resources Cement implemented mid-year dividends in 2025, with a dividend payout ratio of 29%, marking Conch's first mid-year dividend [4]

证券研究报告 | 2025年09月10日 自营轮动加快，海外谋扩张机遇 证券行业 2025 年中报综述暨券业战略转型总结 优于大市 轻资本业务：经纪业务为增长主力，佣金率延续下滑。2025 上半年，A 股日 均交易额为 12,317 亿元，较去年同期+60%；股基交易额达 188.78 万亿（单 边），较去年同期+61%，市场活跃度提升。我们根据中证协的全行业经纪收 入对交易佣金率进行测算，2025 年上半年证券行业佣金率为 0.0182%，较 2024 年上半年有所降低，经纪业务竞争持续激烈。投行业务，境内股承同比 有所改善，境外股承实现高增。资管业务，伴随行情复苏，公募基金对母公 司业绩贡献逐步增加，私募资管受益于银行理财委外规模增长。 国际业务：加快海外业务及数字资产等创新业务布局。一方面，中资券商加 速海外布局，持续提升国际竞争力。头部券商综合实力强劲，国际业务处领 先地位。另一方面，RWA 等创新业务为中资券商展业提供机遇。当前，部分 券商积极申请相关牌照，也将传统业务向数字资产、虚拟资产领域深度拓展。 投资建议：当前，中证证券全指 PB 估值为 1.56 倍，略高于近 5 年均值，我 们维持行业" ...

Core Viewpoint - Changan Automobile is actively engaging in product launches, sales growth, and strategic planning for future industries and global expansion, showcasing a strong commitment to innovation and market penetration [1][2][3][4][5][6]. Product Launches - Changan has recently intensified its product launch schedule, with the fourth-generation Yidong officially launched on September 7 and the fourth-generation CS55PLUS expected to be released by the end of the year [2]. - The Changan Qiyuan brand introduced two new models, A06 and Q05, at the Fifth Technology Ecology Conference, with the Q05 featuring a 506 km electric range and advanced technologies [2]. Sales Performance - In August 2025, Changan sold 234,000 vehicles, marking a 25% year-on-year increase, with total sales from January to August reaching 1.8 million units, up 6.4% [3]. - The company's new energy vehicle sales for the same period totaled 621,000 units, reflecting a significant 55.9% increase year-on-year [3]. Intelligent Driving Solutions - Changan's "Tianshu Intelligent Driving" brand aims to provide extreme safety and intelligent travel solutions, utilizing advanced technologies in driving assistance, cabin experience, and chassis systems [4]. Future Industry Layout - Changan is exploring new technologies in humanoid robots and unmanned commercial vehicles, with plans to mass-produce humanoid automotive robots by 2028 [5]. Global Expansion Strategy - Changan is accelerating its global "Haina Baichuan" plan, having established a presence in over 100 countries and planning to open 20 overseas factories, with a target production capacity of 460,000 units by the end of the year [6].

Summary of Key Points Core Viewpoint - The stock of Guolian Minsheng experienced a decline of 2.75% on September 10, closing at 10.97 yuan, with significant block trades occurring during the day [1]. Trading Activity - A total of three block trades were executed, with a combined trading volume of 1.528 million shares and a total transaction value of 16.76 million yuan [1]. - The first trade involved 1.0428 million shares at a price of 10.97 yuan, amounting to 11.439 million yuan, with a premium rate of 0.00% [1]. - The second trade consisted of 273,500 shares at the same price, totaling 3.0003 million yuan, also with a premium rate of 0.00% [1]. - The third trade involved 211,700 shares, resulting in a transaction value of 2.3221 million yuan, maintaining a premium rate of 0.00% [1]. Recent Performance - Over the past three months, Guolian Minsheng has recorded a total of four block trades, with a cumulative transaction value of 18.7797 million yuan [1]. - In the last five trading days, the stock has seen a cumulative decline of 4.19%, with a net outflow of 73.8353 million yuan in principal funds [1].